Superworth

CervoMed price to sales ratio CRVO

Market value divided by revenue over the last twelve months, since 2013.

Today, Oct 23, 2026
105×
2-year median
9.8×
Against its 2-year history
91st
percentile: 0 is its lowest day, 100 its highest
2-year range
1.6× to 147×
Peer median
0.4×

CervoMed's price to sales ratio is 105× as of Oct 23, 2026.

That is above its 2-year median of 9.8×, higher than on 91% of days in the last 2 years.

Over that time it ranged from 1.6× in Dec 2024 to 147× in Oct 2026.

The median for 4 large drugmakers of a similar size is 0.4×.

Price to sales ratio over time

The dashed line is the 2-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far105×6.0×147×
202512.1×1.7×14.9×
20242.0×1.6×15.9×
2023n/m a value too high to mean anything
2022n/m a value too high to mean anything
2021n/m a value too high to mean anything
2020n/m a value too high to mean anything
2019n/m a value too high to mean anything
2018n/m a value too high to mean anything
2017n/m a value too high to mean anything
2016n/m a value too high to mean anything
2015n/m a value too high to mean anything
201460.6×17.8×63.6×
201317.8×4.4×53.5×

Against its peers

Companies in Drug Manufacturers - General nearest CervoMed's size, closest first, today.

CompanyPrice to sales ratio
CRVOCervoMed105×
ATNMActinium Pharmaceuticalsn/m
SPROSpero Therapeutics1.4×
LFVNLifevantage0.4×
NATRNatures Sunshine Products0.4×
Peer median0.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on CervoMed

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.